This study shows that, even in the pre-temozolomide era, grade 4 astrocytomas, associated with the TP53 mutation, have a better outcome (median survival of 7.8 months) compared to GBMs (median survival of 4.7 months). This evidence concerns the gene TP53 and astrocytoma (excluding glioblastoma).